Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed
Despite industry headwinds, Envista, BioLife Solutions, InfuSystems and MariMed are leveraging innovation and strategy for growth.
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
4 Stocks Trading Near 52-Week High With More Upside Potential
Stocks like FHI, NVST, COMM and FLS are seeing price strength and have a high chance of carrying the momentum forward.
Earnings Estimates Moving Higher for Envista ( NVST ) : Time to Buy?
Envista (NVST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
4 GARP Stocks With Solid PEG Scores for Strong Portfolio Gains
Four GARP picks with low PEG ratios and strong growth potential include Kontoor Brands, Envista, Western Digital and LATAM Airlines.
Why Envista ( NVST ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Price Over Earnings Overview: Envista Holdings - Envista Holdings ( NYSE:NVST )
In the current session, the stock is trading at $20.20, after a 0.55% spike. Over the past month, Envista Holdings Inc. NVST stock increased by 0.32%, and in the past year, by 24.94%.
NVST vs. ABT: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Envista ( NVST Quick QuoteNVST - ) and Abbott ( ABT Quick QuoteABT - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista Q2 Revenue Jumps 7.7%
Envista ( NYSE:NVST ) , a dental equipment and solutions company serving dental professionals in over 130 countries, announced its second quarter 2025 earnings on July 31, 2025. The standout news was that it surpassed Wall Street estimates on both revenue ( GAAP ) and adjusted earnings per share ...
New Strong Buy Stocks for August 5th
ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.
Interpreting Envista ( NVST ) International Revenue Trends
Explore how Envista's (NVST) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Envista ( NVST ) Q2 Earnings and Revenues Top Estimates
Envista (NVST) delivered earnings and revenue surprises of +8.33% and +6.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. ( AHCO ) Expected to Beat Earnings Estimates: Should You Buy?
AdaptHealth (AHCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Envista ( NVST ) Upgraded to Strong Buy: Here's What You Should Know
Envista (NVST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Golden Cross, Envista ( NVST ) 's Technical Outlook is Bright
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Envista ( NVST ) Earnings Expected to Grow: Should You Buy?
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These Analysts Revise Their Forecasts On General Motors After Q2 Results - General Motors ( NYSE:GM )
General Motors Company GM reported better-than-expected quarterly earnings on Tuesday. The auto behemoth registered second-quarter adjusted earnings per share of $2.53, beating the analyst consensus estimate of $2.40. Quarterly sales of $47.12 billion outpaced the Street view of $45.57 billion.
NVST or ABT: Which Is the Better Value Stock Right Now?
NVST vs. ABT: Which Stock Is the Better Value Option?
General Motors Faces Tariffs Heat, Margins Shrink - General Motors ( NYSE:GM )
GM delivered Q2 adjusted EPS of $2.53 on $47.12 B revenue, topping analyst estimates despite automotive segment sales slipping year‑over‑yea BIT margin plunged to 6.4% from 9.3% as tariff pressures eroded profits.
Elevance Health Q2 Earnings Miss Estimates on Rising Medical Costs
ELV's Q2 EPS slides 12.6% y/y and misses estimates as rising Medicaid and ACA costs weigh on the results.
Encompass Health Opens Rehabilitation Hospital in Florida
EHC opens its 23rd Florida rehab hospital in Daytona Beach, boosting access to care and supporting its 2025 growth plan.
Is Strong Demand for Pickups the Secret to Ford's Q2 Delivery Growth?
F's U.S. sales rise 14.2% in Q2, fueled by strong pickup and hybrid demand, lifting its market share to 14.3%.
BAUSCH & LOMB ALERT: Bragar Eagel & Squire, P.C. is Investigating Bausch + Lomb Corporation on Behalf of Bausch & Lomb Stockholders and Encourages Investors to Contact the Firm - Bausch & Lomb ( NYSE:BLCO )
NEW YORK, June 26, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bausch + Lomb Corporation ( "Bausch & Lomb" or the "Company" ) BLCO on behalf of Bausch & Lomb stockholders.
NVST vs. ABT: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Envista ( NVST Quick QuoteNVST - ) and Abbott ( ABT Quick QuoteABT - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Nobel Biocare and 3Shape Announce Strategic Distribution Partnership
Nobel Biocare to Distribute 3Shape TRIOS® Intraoral Scanners ZURICH, June 23, 2025 /PRNewswire/ -- Nobel Biocare is pleased to announce a new distribution partnership with 3Shape, a global leader in 3D scanning and digital dental solutions.
Should You Add NVST Stock to Your Portfolio Right Now?
Envista's global expansion, smart acquisitions, and strong balance sheet support growth but forex risks remain a drag.
All You Need to Know About Envista ( NVST ) Rating Upgrade to Buy
Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
NVST vs. ABT: Which Stock Is the Better Value Option?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO - Bausch & Lomb ( NYSE:BLCO )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ( "Bausch + Lomb" or the "Company" ) BLCO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO - Bausch & Lomb ( NYSE:BLCO )
NEW YORK, May 13, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ( "Bausch + Lomb" or the "Company" ) BLCO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Understanding Envista ( NVST ) Reliance on International Revenue
Examine the evolution of Envista's (NVST) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
Envista delivers better-than-expected top and bottom-line results for the first quarter of 2025.
GM Trims Outlook, Halts Buyback Amid Tariffs: Sell the Stock Now?
Despite near-term pressure, General Motors still has strong fundamentals in place and is worth holding onto.
Envista ( NVST ) Beats Q1 Earnings and Revenue Estimates
Envista (NVST) delivered earnings and revenue surprises of 20% and 1.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Envista ( NVST ) Q1 Earnings Expected to Decline
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Continue to Hold NVST Stock in Your Portfolio?
Investors are optimistic about Envista, thanks to its strong momentum in the Specialty Products and Technologies segment.
Eberl Claims Service Expands with Strategic Acquisition of Bees360's Drone-Based Property Inspection Services
DENVER, April 01, 2025 ( GLOBE NEWSWIRE ) -- Eberl Claims Service has expanded its technology-driven claims solutions with the acquisition of Bees360's advanced drone based residential and commercial property claims inspection services.
Solventum Partners With SprintRay for Same-Day Dental Restorations
SOLV partners with SprintRay to introduce an innovative solution for same-day dental restorations, enhancing efficiency, precision and patient care in digital dentistry.
Why Is Envista ( NVST ) Down 18.2% Since Last Earnings Report?
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Envista ( NVST ) Down 18.2% Since Last Earnings Report?
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Envista Stock in Your Portfolio for Now
NVST's impressive long-term growth initiatives appear promising. Yet, a leveraged balance sheet is worrisome.
As Trump eyes more tariffs, South Korea remains safe haven for GM and Hyundai
Automakers such as Hyundai Motor and General Motors have increasingly used South Korea as a tariff-free export market to the U.S.
NVST Stock Up on Q4 Earnings and Revenue Beat, Operating Margin Crashes
Envista delivers better-than-expected top and bottom-line results for the fourth quarter of 2024.
Envista ( NVST ) Beats Q4 Earnings and Revenue Estimates
Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Envista ( NVST ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain Envista Stock in Your Portfolio for Now
NVST's strong focus on international market expansion appears promising. Yet, a leveraged balance sheet is worrisome.
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates - NeuroPace ( NASDAQ:NPCE ) , Hyperfine ( NASDAQ:HYPR )
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors effective January 6th Management presenting at the 43rd Annual J.P.
General Motors' Q4 US Sales Rise 21% Y/Y on Robust EV Deliveries
GM's fourth-quarter U.S. sales rise 21% year over year on the back of strong EV sales, which increase 50% year over year to 43,982 units.
Is Envista ( NVST ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
